Literature DB >> 32585491

A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease.

Michael A Sugarman1, Henrik Zetterberg2, Kaj Blennow3, Yorghos Tripodis4, Ann C McKee5, Thor D Stein6, Brett Martin7, Joseph N Palmisano7, Eric G Steinberg8, Irene Simkin9, Andrew E Budson10, Ronald Killiany11, Maureen K O'Connor1, Rhoda Au12, Wendy Wei Qiao Qiu13, Lee E Goldstein14, Neil W Kowall15, Jesse Mez16, Robert A Stern17, Michael L Alosco18.   

Abstract

We examined baseline and longitudinal associations between plasma neurofilament light (NfL) and total tau (t-tau), and the clinical presentation of Alzheimer's disease (AD). A total of 579 participants (238, normal cognition [NC]; 185, mild cognitive impairment [MCI]; 156, AD dementia) had baseline blood draws; 82% had follow-up evaluations. Plasma samples were analyzed for NfL and t-tau using Simoa technology. Baseline plasma NfL was higher in AD dementia than MCI (standardized mean difference = 0.55, 95% CI: 0.37-0.73) and NC (standardized mean difference = 0.68, 95% CI: 0.49-0.88), corresponded to Clinical Dementia Rating scores (OR = 1.94, 95% CI: 1.35-2.79]), and correlated with all neuropsychological tests (r's = 0.13-0.42). Longitudinally, NfL did not predict diagnostic conversion but predicted decline on 3/10 neuropsychological tests. Baseline plasma t-tau was higher in AD dementia than NC with a small effect (standardized mean difference = 0.33, 95% CI: 0.10-0.57) but not MCI. t-tau did not statistically significant predict any longitudinal outcomes. Plasma NfL may be useful for the detection of AD dementia and monitoring of disease progression. In contrast, there was minimal evidence in support of plasma t-tau.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Neurofilament light; Plasma biomarkers; Total tau

Mesh:

Substances:

Year:  2020        PMID: 32585491      PMCID: PMC7484086          DOI: 10.1016/j.neurobiolaging.2020.05.011

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  70 in total

1.  Plasma neurofilament light chain levels in Alzheimer's disease.

Authors:  Wenjun Zhou; Jie Zhang; Fanlong Ye; Guangzheng Xu; Hang Su; Yindan Su; Xiangyang Zhang
Journal:  Neurosci Lett       Date:  2017-04-18       Impact factor: 3.046

2.  Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.

Authors:  Mehtap Bacioglu; Luis F Maia; Oliver Preische; Juliane Schelle; Anja Apel; Stephan A Kaeser; Manuel Schweighauser; Timo Eninger; Marius Lambert; Andrea Pilotto; Derya R Shimshek; Ulf Neumann; Philipp J Kahle; Matthias Staufenbiel; Manuela Neumann; Walter Maetzler; Jens Kuhle; Mathias Jucker
Journal:  Neuron       Date:  2016-07-20       Impact factor: 17.173

Review 3.  Biomarkers for Alzheimer's disease: current status and prospects for the future.

Authors:  K Blennow; H Zetterberg
Journal:  J Intern Med       Date:  2018-08-19       Impact factor: 8.989

Review 4.  CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Obioha Ukoumunne; Emma C Ladds; Steven Martin
Journal:  Cochrane Database Syst Rev       Date:  2017-03-22

5.  Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.

Authors:  Diego Albani; Moira Marizzoni; Clarissa Ferrari; Federica Fusco; Lucia Boeri; Ilaria Raimondi; Jorge Jovicich; Claudio Babiloni; Andrea Soricelli; Roberta Lizio; Samantha Galluzzi; Libera Cavaliere; Mira Didic; Peter Schönknecht; José Luis Molinuevo; Flavio Nobili; Lucilla Parnetti; Pierre Payoux; Luisella Bocchio; Marco Salvatore; Paolo Maria Rossini; Magda Tsolaki; Pieter Jelle Visser; Jill C Richardson; Jens Wiltfang; Régis Bordet; Olivier Blin; Gianluigi Forloni; Giovanni B Frisoni
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

6.  Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

Authors:  Lucilla Parnetti; Pietro Tiraboschi; Alessia Lanari; Maria Peducci; Chiara Padiglioni; Cataldo D'Amore; Laura Pierguidi; Nicola Tambasco; Aroldo Rossi; Paolo Calabresi
Journal:  Biol Psychiatry       Date:  2008-04-08       Impact factor: 13.382

7.  Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.

Authors:  Oliver Preische; Stephanie A Schultz; Anja Apel; Jens Kuhle; Stephan A Kaeser; Christian Barro; Susanne Gräber; Elke Kuder-Buletta; Christian LaFougere; Christoph Laske; Jonathan Vöglein; Johannes Levin; Colin L Masters; Ralph Martins; Peter R Schofield; Martin N Rossor; Neill R Graff-Radford; Stephen Salloway; Bernardino Ghetti; John M Ringman; James M Noble; Jasmeer Chhatwal; Alison M Goate; Tammie L S Benzinger; John C Morris; Randall J Bateman; Guoqiao Wang; Anne M Fagan; Eric M McDade; Brian A Gordon; Mathias Jucker
Journal:  Nat Med       Date:  2019-01-21       Impact factor: 53.440

8.  Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.

Authors:  Ester Cantó; Christian Barro; Chao Zhao; Stacy J Caillier; Zuzanna Michalak; Riley Bove; Davorka Tomic; Adam Santaniello; Dieter A Häring; Jill Hollenbach; Roland G Henry; Bruce A C Cree; Ludwig Kappos; David Leppert; Stephen L Hauser; Pascal Benkert; Jorge R Oksenberg; Jens Kuhle
Journal:  JAMA Neurol       Date:  2019-11-01       Impact factor: 18.302

9.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.

Authors:  Suzanne E Schindler; James G Bollinger; Vitaliy Ovod; Kwasi G Mawuenyega; Yan Li; Brian A Gordon; David M Holtzman; John C Morris; Tammie L S Benzinger; Chengjie Xiong; Anne M Fagan; Randall J Bateman
Journal:  Neurology       Date:  2019-08-01       Impact factor: 11.800

10.  Vascular dysfunction-The disregarded partner of Alzheimer's disease.

Authors:  Melanie D Sweeney; Axel Montagne; Abhay P Sagare; Daniel A Nation; Lon S Schneider; Helena C Chui; Michael G Harrington; Judy Pa; Meng Law; Danny J J Wang; Russell E Jacobs; Fergus N Doubal; Joel Ramirez; Sandra E Black; Maiken Nedergaard; Helene Benveniste; Martin Dichgans; Costantino Iadecola; Seth Love; Philip M Bath; Hugh S Markus; Rustam Al-Shahi Salman; Stuart M Allan; Terence J Quinn; Rajesh N Kalaria; David J Werring; Roxana O Carare; Rhian M Touyz; Steve C R Williams; Michael A Moskowitz; Zvonimir S Katusic; Sarah E Lutz; Orly Lazarov; Richard D Minshall; Jalees Rehman; Thomas P Davis; Cheryl L Wellington; Hector M González; Chun Yuan; Samuel N Lockhart; Timothy M Hughes; Christopher L H Chen; Perminder Sachdev; John T O'Brien; Ingmar Skoog; Leonardo Pantoni; Deborah R Gustafson; Geert Jan Biessels; Anders Wallin; Eric E Smith; Vincent Mok; Adrian Wong; Peter Passmore; Frederick Barkof; Majon Muller; Monique M B Breteler; Gustavo C Román; Edith Hamel; Sudha Seshadri; Rebecca F Gottesman; Mark A van Buchem; Zoe Arvanitakis; Julie A Schneider; Lester R Drewes; Vladimir Hachinski; Caleb E Finch; Arthur W Toga; Joanna M Wardlaw; Berislav V Zlokovic
Journal:  Alzheimers Dement       Date:  2019-01       Impact factor: 16.655

View more
  12 in total

Review 1.  Promising Blood Biomarkers for Clinical Use in Alzheimer's Disease: A Focused Update.

Authors:  Sun Ah Park; Yu Jung Jang; Min Kyoung Kim; Sun Min Lee; So Young Moon
Journal:  J Clin Neurol       Date:  2022-07       Impact factor: 2.566

2.  Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment.

Authors:  Pia Kivisäkk; Colin Magdamo; Bianca A Trombetta; Ayush Noori; Yi Kai E Kuo; Lori B Chibnik; Becky C Carlyle; Alberto Serrano-Pozo; Clemens R Scherzer; Bradley T Hyman; Sudeshna Das; Steven E Arnold
Journal:  Brain Commun       Date:  2022-06-14

3.  Plasma p-tau181 shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau.

Authors:  Brandon Frank; Madeline Ally; Bailee Brekke; Henrik Zetterberg; Kaj Blennow; Michael A Sugarman; Nicholas J Ashton; Thomas K Karikari; Yorghos Tripodis; Brett Martin; Joseph N Palmisano; Eric G Steinberg; Irene Simkina; Katherine W Turk; Andrew E Budson; Maureen K O'Connor; Rhoda Au; Lee E Goldstein; Gyungah R Jun; Neil W Kowall; Thor D Stein; Ann C McKee; Ronald Killiany; Wei Qiao Qiu; Robert A Stern; Jesse Mez; Michael L Alosco
Journal:  Alzheimers Dement       Date:  2021-12-02       Impact factor: 16.655

4.  Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease.

Authors:  Zhenxu Xiao; Xue Wu; Wanqing Wu; Jingwei Yi; Xiaoniu Liang; Saineng Ding; Li Zheng; Jianfeng Luo; Hongchen Gu; Qianhua Zhao; Hong Xu; Ding Ding
Journal:  Alzheimers Res Ther       Date:  2021-07-05       Impact factor: 6.982

Review 5.  State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementia-A Short Review and Diagnostic Algorithm.

Authors:  Eino Solje; Alberto Benussi; Emanuele Buratti; Anne M Remes; Annakaisa Haapasalo; Barbara Borroni
Journal:  Diagnostics (Basel)       Date:  2021-04-27

6.  Cerebral amyloid-β load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum.

Authors:  Gemma Salvadó; Marta Milà-Alomà; Mahnaz Shekari; Carolina Minguillon; Karine Fauria; Aida Niñerola-Baizán; Andrés Perissinotti; Gwendlyn Kollmorgen; Christopher Buckley; Gill Farrar; Henrik Zetterberg; Kaj Blennow; Marc Suárez-Calvet; José Luis Molinuevo; Juan Domingo Gispert
Journal:  Alzheimers Dement       Date:  2021-03-04       Impact factor: 21.566

7.  Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.

Authors:  Maria Carmona-Iragui; Daniel Alcolea; Isabel Barroeta; Laura Videla; Laia Muñoz; Kathyrn L Van Pelt; Frederick A Schmitt; Donita D Lightner; Lisa M Koehl; Gregory Jicha; Silvia Sacco; Clotilde Mircher; Sarah E Pape; Rosalyn Hithersay; Isabel C H Clare; Anthony J Holland; Georg Nübling; Johannes Levin; Shahid H Zaman; Andre Strydom; Anne-Sophie Rebillat; Elizabeth Head; Rafael Blesa; Alberto Lleó; Juan Fortea
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 59.935

8.  Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Xulong Ding; Shuting Zhang; Lijun Jiang; Lu Wang; Tao Li; Peng Lei
Journal:  Transl Neurodegener       Date:  2021-03-12       Impact factor: 8.014

9.  Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.

Authors:  Jordan D Marks; Jeremy A Syrjanen; Jonathan Graff-Radford; Ronald C Petersen; Mary M Machulda; Michelle R Campbell; Alicia Algeciras-Schimnich; Val Lowe; David S Knopman; Clifford R Jack; Prashanthi Vemuri; Michelle M Mielke
Journal:  Alzheimers Res Ther       Date:  2021-12-14       Impact factor: 6.982

10.  Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria.

Authors:  Daniela Kern; Michael Khalil; Lukas Pirpamer; Arabella Buchmann; Edith Hofer; Peter Dal-Bianco; Elisabeth Stögmann; Christoph Scherfler; Thomas Benke; Gerhard Ransmayr; Reinhold Schmidt
Journal:  Medicina (Kaunas)       Date:  2022-03-16       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.